Drugs / Inobrodib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04068597 | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03568656 | Jul 2018 → Jul 2025 | breast cancer, castration-resistant prostate carcinoma, non-small cell lung carcinoma | CellCentric Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07096778 | Jan 2026 → Dec 2029 expected | plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2025-12-07 | CellCentric Ltd. | Results CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting cellcentric.com ↗
Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients |
| 2025-11-03 | CellCentric Ltd. | Results CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting cellcentric.com ↗
Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile in a heavily pretreated population |
| 2024-12-10 | CellCentric Ltd. | Results CellCentic Presents Latest Clinical Data at ASH: Promising Efficacy and Safety in Multiple Myeloma cellcentric.com ↗
The data shared at ASH highlights the encouraging efficacy and manageable safety profile of inobrodib in combination with pomalidomide and dexamethasone in heavily pre-treated RRMM patients, including those who have failed multiple prior treatments. |
| 2023-12-11 | CellCentric Ltd. | Results CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials cellcentric.com ↗
The data shows over 70% responses (>=MR by IMWG criteria) in last line multiple myeloma patients treated with inobrodib in combination with pom + dex. |
| 2023-11-22 | CellCentric Ltd. | Results Inobrodib’s novel mechanism: new data published in Cancer Cell cellcentric.com ↗
The paper also describes initial data from a Phase 1a/2b haematological malignancy clinical trial. |
| 2023-06-29 | CellCentric Ltd. | Regulatory CellCentric Granted FDA Orphan Drug Designation for Inobrodib (CCS1477) for the Treatment of Multiple Myeloma cellcentric.com ↗
CellCentric, a UK-based biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib (CCS1477) in the treatment of multiple myeloma. |
| 2023-06-13 | CellCentric Ltd. | Regulatory CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma cellcentric.com ↗
CellCentric today announces that the US Food and Drug Administration (FDA) has granted its novel cancer drug inobrodib Fast Track designation for the treatment of patients with relapsed or refractory multiple myeloma. |
| 2022-12-11 | CellCentric Ltd. | Results CellCentric presents early haem clinical data at ASH cellcentric.com ↗
Among the patients treated at the RP2D, six out of seven patients had reduction or stabilisation of serum free light chains. |
| 2022-11-04 | CellCentric Ltd. | Results CellCentric to present haem clinical data at ASH cellcentric.com ↗
Objective responses have been observed in multiple settings, including as monotherapy in relapsed refractory multiple myeloma |
| 2021-04-27 | CellCentric Ltd. | Regulatory IND Open: CellCentric expanding clinical trials into the US cellcentric.com ↗ |
| 2021-01-11 | CellCentric Ltd. | Results CellCentric’s first-in-class p300/CBP inhibitor CCS1477 publishes in Cancer Discovery cellcentric.com ↗
In the paper published online today in Cancer Discovery, data is presented that shows the impact of CCS1477 on AR, AR-SV and c-Myc in a range of pre-clinical models. |
| 2018-06-25 | CellCentric Ltd. | Regulatory CellCentric enters clinic with first-in-class p300/CBP inhibitor for late-stage prostate cancer cellcentric.com ↗
The clinical trial has been initiated following regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA). |
| 2017-12-04 | CellCentric Ltd. | Results CellCentric’s p300/CBP bromodomain inhibitor is clearly differentiated from BET inhibitors cellcentric.com ↗
CellCentric today presents its latest pre-clinical efficacy data on drug Candidate CCS1477, at the AACR’s Annual Prostate Cancer meeting, Orlando. |
| 2017-10-05 | CellCentric Ltd. | Results CellCentric presents at the Prostate Cancer Foundation annual retreat, Washington DC cellcentric.com ↗
In pre-clinical models of CRPC, the compound’s inhibitory effects are profound and sustained. |
| 2017-04-03 | CellCentric Ltd. | Results CellCentric presents further CCS1477 pre-clinical efficacy data at AACR cellcentric.com ↗
The compound has been proven effective in an in vivo xenograft model of 22Rv1 cancer cells that express full length AR and AR splice variants. |
| 2017-02-16 | CellCentric Ltd. | Results CellCentric’s novel p300/CBP inhibitor, CCS1477 advancing to the clinic cellcentric.com ↗
Data shared today shows that CellCentric’s candidate drug CCS1477 lowers AR and AR-splice variants, as well as the key cancer regulator c-Myc, causing complete inhibition of prostate tumour growth in vivo (22Rv1 xenograft). |
All press releases naming this drug 28 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inobrodib | “Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies” NCT04068597 ↗ |
| Known as | CCS1477 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03568656 ↗ |
| Modality | Small molecule | — CHEMBL4785363 ↗ |
| Route | Oral | “Capsules, oral” NCT03568656 ↗ |